Drug Trial Radar · NCT04843449
Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Aug 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Apr 4, 2021
Primary completion
May 6, 2021
Study completion May 14, 2021
Sponsor
- Lead sponsor
- Ascletis Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effects of itraconazole (a strong inhibitor of cytochrome P450 3A (CYP3A)) and rifampicin (a strong inducer of CYP3A) on the pharmacokinetics of ASC40 in healthy volunteers.
Conditions
- Healthy
Interventions
ASC40Drug
Oral tablets
ItraconazoleDrug
Oral capsules
rifampicinDrug
Oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC of ASC40Time frame: Up to 24 days
- Cmax of ASC40Time frame: Up to 24 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hunan provincial people's hospital
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.